SCHEMBL26601795

SCHEMBL26601795

Clc1cc(Cl)c2c(n1)CCCS2

nearest known ligand 0.34

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TNKS O95271 1/20 0.34
PARP1 P09874 1/20 0.34
WNT3A P56704 1/20 0.34
TNKS2 Q9H2K2 1/20 0.34
PARP2 Q9UGN5 1/20 0.34
PDE4B Q07343 2/20 0.32
PDE4D Q08499 2/20 0.32
NPC1 O15118 2/20 0.32
MAPT P10636 2/20 0.32
RAB9A P51151 2/20 0.32
SMN1; SMN2 Q16637 2/20 0.32
MEN1 O00255 1/20 0.32
ALDH1A1 P00352 1/20 0.32
POLB P06746 1/20 0.32
BLM P54132 1/20 0.32
KMT2A Q03164 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
ACHE P22303 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30712008 0.89 SMN1; SMN2 (0.38) NPC1MAPTRAB9ASMN1; SMN2MEN1
SCHEMBL21062014 0.89 SMN1; SMN2 (0.38) NPC1MAPTRAB9ASMN1; SMN2MEN1
SCHEMBL26601781 0.70 AKT1 (0.38) PDE4BPDE4DSMN1; SMN2
SCHEMBL31517751 0.70 AKT1 (0.38) PDE4BPDE4DSMN1; SMN2
SCHEMBL7389179 0.69 TNKS (0.33) TNKSPARP1WNT3ATNKS2PARP2
SCHEMBL2624108 0.68 ACHE (0.49) MAPTMEN1KMT2AACHE
SCHEMBL30225174 0.68 ACHE (0.45) MEN1ALDH1A1POLBKMT2AL3MBTL1
SCHEMBL3467970 0.68 ACHE (0.45) MEN1ALDH1A1POLBKMT2AL3MBTL1
Hydrochloric Acid SCHEMBL16668879 0.67 ACHE (0.47) MEN1KMT2AACHE
Hydrochloric Acid SCHEMBL29710413 0.67 ACHE (0.47) MEN1KMT2AACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250388541-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN VERTEX PHARMACEUTICALS INCORPORATED (US) 2025-12-25 US disclosed
EP-4511117-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN Vertex Pharmaceuticals Incorporated (US) 2025-02-26 EP disclosed
WO-2023205465-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN VERTEX PHARMACEUTICALS INCORPORATED (US) 2023-10-26 WO disclosed
WO-2023205465-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN VERTEX PHARMACEUTICALS INCORPORATED (US) 2023-10-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250388541-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN SCN1B, CLIC1, HCN1 TNKS 4308/4885PARP1 3996/4885WNT3A 1702/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.